Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a theoretical combination of four distinct drugs with different mechanisms of action and therapeutic uses. The combination includes: - **Scopolamine**: An anticholinergic muscarinic antagonist used for motion sickness, postoperative nausea and vomiting, and other conditions - **Atropine**: A related muscarinic antagonist used in ophthalmology and for bradycardia treatment - **Edaravone**: A free radical scavenger used for ALS and ischemic stroke - **Dexmedetomidine**: An α2 adrenergic receptor agonist used for sedation and analgesia There is no evidence that these four drugs are used together as an established combination product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on scopolamine + atropine + edaravone + dexmedetomidine.